slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment

Lund, K., Dembinski, J. L., Solberg, N., Urbanucci, A., Mills, I. G., & Krauss, S. (2015). Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PloS one, 10(4), e0123684. https://doi.org/10.1371/journal.pone.0123684

Published in:
PloS one

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2015 Lund et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
 Slug-Dependent Upregulation of L1CAM Is Responsible for the Increased Invasion Potential of Pancreatic Cancer Cells following Long-Term 5-FU Treatment

Kaja Lund1‡*, Jennifer L. Dembinski1,5‡, Nina Solberg1, Alfonso Urbanucci2,3, Ian G. Mills2,3,4, Stefan Krauss1

1 Unit for Cell Signaling, Institute of Microbiology, Cancer Stem Cell, Innovation Center (CAST), Rikshospitalet, Oslo, Norway, 2 Centre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, Oslo, Norway, 3 Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, 4 Department of Urology, Oslo University Hospital, Oslo, Norway, 5 Norwegian Institute of Public Health, Division of Infectious Disease Control, Department of Bacteriology and Immunology, Oslo, Norway

‡ These authors are co-first authors on this work.
* kaja.lund@rr-research.no

Abstract

Background

Pancreatic adenocarcinoma is a lethal disease with 5-year survival of less than 5%. 5-fluorouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly and is seldom curative. Drug resistance and disease recurrence is typical and there is a pressing need to overcome this. To investigate acquired 5-FU resistance in pancreatic adenocarcinoma, we established chemoresistant monoclonal cell lines from the Panc 03.27 cell line by long-term 5-FU treatment.

Results

5-FU-resistant cell lines exhibited increased expression of markers associated with multidrug resistance explaining their reduced sensitivity to 5-FU. In addition, 5-FU-resistant cell lines showed alterations typical for an epithelial-to-mesenchymal transition (EMT), including upregulation of mesenchymal markers and increased invasiveness. Microarray analysis revealed the L1CAM pathway as one of the most upregulated pathways in the chemoresistant clones, and a significant upregulation of L1CAM was seen on the RNA and protein level. In pancreatic cancer, expression of L1CAM is associated with a chemoresistant and migratory phenotype. Using esiRNA targeting L1CAM, or by blocking the extracellular part of L1CAM with antibodies, we show that the increased invasiveness observed in the chemoresistant cells functionally depends on L1CAM. Using esiRNA targeting β-catenin and/or Slug, we demonstrate that in the chemoresistant cell lines, L1CAM expression depends on Slug rather than β-catenin.
Conclusion

Our findings establish Slug-induced L1CAM expression as a mediator of a chemoresistant and migratory phenotype in pancreatic adenocarcinoma cells.

Introduction

Pancreatic adenocarcinoma is an extremely deadly disease. The early course of the disease is often asymptomatic leading to only 8% of cases being diagnosed at this stage. The outlook for late-stage adenocarcinoma patients is bleak, with only 20% of patients being candidates for surgery (due to late diagnosis/tumor metastasis), resulting in a 5-year survival of less than 5% [1]. Current treatment options available may extend survival and relieve symptoms in patients, but are not curative in most cases.

5-Fluorouracil (5-FU) has for a long time been an established form of chemotherapy for pancreatic adenocarcinoma, together with the drug gemcitabine [2]. However, inherent (de novo) and acquired resistance are major obstacles for the success of 5-FU based chemotherapy in pancreas adenocarcinoma and other tumors [3]. Acquired drug resistance, which develops during treatment, is often manifested by several resistant mechanism and is therefore therapeutically difficult to reverse.

5-FU decreases the biosynthesis of pyrimidine nucleotides by inhibiting thymidylate synthase (TS), an enzyme that catalyzes the rate-limiting step in DNA synthesis [4]. Although the mechanisms of resistance to 5-FU remains unclear, several reports have linked chemoresistance in various solid tumor cell lines to epithelial-to-mesenchymal transition (EMT) [5–8]. EMT is a fundamental embryological process characterized by alterations in morphology, cellular architecture, signaling and adhesion leading to a migratory phenotype [9]. When EMT occurs in tumor cells, these cells lose their epithelial features and acquire a more invasive and migratory phenotype leading to augmented metastatic potential. Molecular markers for EMT include increased expression of vimentin and N-cadherin and increased expression of transcription factors that repress E-cadherin expression, including Twist, Snail, and Slug [10].

The L1 cell adhesion molecule (L1CAM) is a highly conserved transmembrane glycoprotein of the immunoglobulin superfamily that was first identified to play a part in the development and regeneration of neuronal tissue [11]. L1CAM expression has been observed in a number of cancer cell lines and tissues, and high L1CAM expression is often associated with poor prognosis and short survival times [12]. L1CAM has been linked to EMT in several different cancer types, including pancreatic cancer [13–18]. In particular, L1CAM has been associated with a chemoresistant and migratory phenotype in pancreatic ductal adenocarcinoma (PDAC) [19–21]. To investigate the mechanisms involved in the acquisition of 5-FU resistance, we established 5-FU-resistant clones from the pancreatic adenocarcinoma cell line Panc 03.27, and subjected the cell lines to functional tests and microarray analysis. The chemoresistant Panc 03.27 cells underwent phenotypic changes consistent with an EMT, and the expression of EMT-related markers, particularly L1CAM, increased substantially. Knockdown studies showed that the L1CAM expression in the 5-FU-resistant clones was dependent on the transcription factor Slug but not on β-catenin, and knockdown of L1CAM confirmed a functional link between L1CAM and the proliferative and invasive potential of the chemoresistant Panc 03.27 clones. Knockdown studies further showed that L1CAM moderately protected chemoresistant B1V cells from apoptosis induced by 5-FU. Our findings provide further insight into the molecular mechanisms leading to a chemoresistant and migratory phenotype in pancreatic cancer cells.
and highlight the importance of addressing Slug-induced L1CAM expression in recurrent PDAC.

Results

Development of 5-FU-resistant clones

Panc 03.27 5-FU-resistant cell lines were generated by continuous exposure of the tumor cells to 5-FU over a 6 month period, starting at 0.5 μg/ml 5-FU and increased to 1 μg/ml over time. To verify the dose dependent chemoresistance of the obtained clones, a dose curve was run to a range of 5-FU concentrations (0.5–10 μg/ml) over a 6 day period. As expected, clones that were grown without 5-FU selection (named Nt and Nw) were sensitive to all concentrations of 5-FU. In the chemoresistant clones B1Q and B1V normal growth was seen with doses up to 1 μg/ml 5-FU, while the higher concentrations of 5-FU (5–10 μg/ml) still inhibited growth (Fig 1A).

5-FU-resistant clones display resistance mechanisms

5-FU sensitivity has been shown to be inversely related to the level of thymidine synthase (TS) protein in cancer cells, and 5-FU-resistant tumors commonly express high levels of TS protein [22,23]. High expression of TS in cancer tissue is an indicator of poor prognosis for 5-FU-based chemotherapy for colorectal cancer patients [24]. The protein level of TS was analyzed in all four clones. TS was drastically increased in the chemoresistant clones B1Q and B1V, as shown by Western blot analysis (Fig 1B). Using taqman RT-PCR, we next analyzed the RNA levels of efflux pumps associated with 5-FU- and multidrug resistance [25,26]. We observed a statistically relevant increase in the expression of the efflux pumps ABCB1 (MDR1) and ABCC5 (MRP5) in the chemoresistant clones as compared to the chemosensitive clones (Fig 1C). The level of survivin was also greatly increased in the chemoresistant clones as assessed by Western blotting (Fig 1D). Survivin is an inhibitor of apoptosis expressed in the G2/M phase of the cell cycle and overexpression of survivin is linked to resistance to apoptotic stimuli induced by chemotherapeutic drugs [27,28].

5-FU-resistant clones display morphological changes that are associated with EMT

When the morphology of the 5-FU-resistant clones was compared to the sensitive clones, the former displayed a more mesenchymal-like phenotype, with cell scattering and increased formation of pseudopodia, while the sensitive clones display a tightly packed epithelial morphology (Fig 2A). The 5-FU-resistant cells appeared larger and more stretched out than the sensitive cells. The mesenchymal-like phenotype, which was maintained for over 30 passages, is in line with previous observations of drug-induced chemoresistance in cell lines [29,30]. Important hallmarks of EMT are a downregulation of the epithelial marker E-cadherin accompanied by an upregulation of N-cadherin and vimentin [9]. Accordingly, the chemoresistant clones showed an increase in vimentin (Fig 2B and 2E) and N-cadherin (Fig 2D and 2G) on both protein and RNA levels, and a downregulation of E-cadherin (Fig 2C and 2F). Cytokeratin 19 (CK19) is an intermediate filament that is in part responsible for the structural integrity of cells. Various cytoskeletal modifications within a cell are associated with malignant transformation, and a loss of CK19 has been associated with EMT [31] and multidrug resistance [32]. When the Nt, Nw, B1Q and B1V clones were analyzed for the expression of CK19 by immuno-cytochemistry and Western blot, a massive reduction of CK19 was found in the chemoresistant clones as compared to the 5-FU sensitive clones (Fig 2H and 2I). To evaluate if the changed
morphology that was observed in the chemoresistant clones was functionally significant, we examined the invasive properties of the clones using a matrigel invasion assay (Fig 2J and 2K). Chemoresistant clones B1Q and B1V were 4 to 6 times more invasive than the two chemosensitive clones Nt and Nw.
Fig 2. 5-FU-resistant clones display morphological changes that are associated with EMT. (A) Phase contrast photos showing cell morphology of normal (Nw, Nt) and chemoresistant clones (B1Q, B1V), 40x. (B-D) RNA levels (relative quantity) of vimentin, E-cadherin, and N-cadherin, as measured by RTPCR. (E) Western blot analysis of vimentin and actin. (F) Western blot analysis of E-cadherin and actin. (G) Immunofluorescence staining for vimentin, E-cadherin, and cytokeratin 19. (H) Immunofluorescence staining for actin. (I) Immunofluorescence staining for vimentin and actin. (J) Graph showing the number of cells stained for actin, with statistical significance indicated by an asterisk (P < 0.05).
L1CAM is upregulated in the 5-FU-resistant cells

In order to establish a more exhaustive molecular profile between the sensitive and non-sensitive cell lines, we performed microarray analysis including the 5-FU resistant cell line B1V and the chemosensitive clone Nt. 607 genes were considered as they presented with log2 change > 1 (S1 Fig). 319 genes were found to be upregulated and 288 genes were downregulated at least 2-fold in B1V compared to Nt (P < 0.05) (S1 and S2 Tables, respectively). Gene Ontology analysis of the 319 upregulated genes revealed that the L1CAM interaction pathway was one of the most upregulated pathways in the chemoresistant clones, together with cytokine and inflammatory responses (Fig 3A). L1CAM itself was upregulated 4 times in the B1V cells compared to the Nt cells. Hallmarks of Wnt signaling and pluripotency, apoptosis, serotonin transporter activity, monoamine transport and glycogen metabolism were also found to be upregulated in the B1V chemoresistant cell line (Fig 3A and S1 Table).

The increase in L1CAM in the chemoresistant clones was confirmed by real-time PCR (P<0.05) and Western blot analysis (Fig 3B and 3C, respectively). Furthermore, flow cytometric analysis using a PE-conjugated anti-L1CAM antibody showed enrichment of L1CAM positive cells in the B1Q and B1V cell lines (Fig 3D). In support of this observation, immunohistochemistry revealed a distinct L1CAM expression in the membrane of the chemoresistant clones B1Q and B1V but not in the chemosensitive cells Nt and Nw (Fig 3E). A proportion of the chemoresistant cells also exhibited nuclear L1CAM immunoreactivity.

L1CAM is involved in proliferation and invasiveness of the 5-FU-resistant clones, and moderately protects the chemoresistant cells from 5-FU-induced apoptosis

EMT has been associated with an increased invasiveness of tumor cells [33], and previously published reports showed that L1CAM triggers cell migration and invasion in several tumor types [15,18,34]. To investigate whether the upregulation of L1CAM is involved in the increased invasion potential of the chemoresistant cells, the expression of L1CAM was knocked down using esiRNA. esiRNA are endoribonuclease-prepared siRNA pools comprised of a heterogeneous mixture of siRNAs that all target the same mRNA sequence. esiRNA treatment dramatically reduced the protein level of L1CAM in the chemoresistant cell lines B1Q and B1V (Fig 4A), compared to cells transfected with control esiRNA (targeting EGFP). When assayed for invasiveness in a matrigel invasion chamber the number of invasive cells after L1CAM knockdown was significantly lower compared to the negative control after 24 h invasion (Fig 4B). To further assess the relationship between the invasiveness of the chemoresistant clones and L1CAM expression, cells were treated with either an antibody targeting the extracellular part of L1CAM (clone UJ127.11), or a mouse isotype control antibody, prior to an invasion assay experiment (invasion assay times were increased to 48 hours). Our results show that treating B1Q and B1V cells with the L1CAM antibody significantly reduced their invasiveness compared to treatment with the control antibody. By contrast, treating chemosensitive Nt and Nw cells with L1CAM antibody had no effect on invasiveness (Fig 4C).
Overexpression of L1CAM has been shown to promote tumor cell proliferation, and accordingly, inhibition of L1CAM expression or function can suppress proliferation [35–37]. To investigate whether knockdown of L1CAM had an influence on cell growth in the chemoresistant cells, we performed in vitro proliferation assays. All cell lines were subjected to L1CAM and control esiRNA treatment, and the percentage confluence was measured over time by an IncuCyte automated reader (Fig 4D). Measurements started 24 hours after esiRNA transfection. We have previously observed that the effect of esiRNA knockdown on protein level gradually diminishes after 72 hours (results not shown), but to obtain a proper growth curve the experiments were run for at least 96 hours post transfection. The growth curves showed no effect of the esiRNA treatment targeting L1CAM on the chemosensitive cell lines Nt and Nw. However, the chemoresistant cell lines B1Q and B1V displayed significantly reduced growth following L1CAM knockdown (Fig 4D) demonstrating that L1CAM expression is involved in cell proliferation of the chemoresistant cells.

When the anti-L1CAM antibody that inhibited invasion in the chemoresistant cells was added to in vitro proliferation assays, we could not see any difference in percentage cell confluence between cells treated with the antibody compared to cells treated with the control antibody. This was performed on all four cell lines.

L1CAM has been shown to play a role in the mediation of chemoresistance against gemcitabine and etoposide in PDAC cell lines [38]. To assess whether the L1CAM was involved in mediating resistance to 5-FU in the chemoresistant Panc 03.27 cell lines, Annexin V flow cytometric assays were carried out in Nt and B1V cells 72 hours after cells were treated with L1CAM or control esiRNA in the presence and absence of 1 μg/ml 5-FU. As expected, Nt cells treated with a control esiRNA showed a significant shift towards Annexin V positive cells after being exposed to 5-FU (from 0.87% to 18.32%). In contrast, control treated B1V cells did only show a slight increase (from 1.19% to 2.22%) in Annexin V positive cells in response to 5-FU treatment (Fig 4E and 4F). Knockdown of L1CAM did not significantly alter the rates of apoptosis in the chemosensitive cell line Nt, either in the presence or absence of 5-FU treatment when compared to the ctrl knockdown (Fig 4E). However, knockdown of L1CAM increased percentage Annexin V positive cells, both with or without 5-FU treatment. Thus, L1CAM appears to moderately protect chemoresistant B1V cells from apoptosis in the absence of 5-FU, and more so in the presence of 5-FU (Fig 4F).

Transcriptional regulation of L1CAM depends on Slug, but not on β-catenin

Previous studies have implicated both Slug and β-catenin in the transcriptional regulation of L1CAM [14,39–41]. Slug is a transcriptional factor that is involved in EMT and invasiveness in pancreatic cancer [34,42]. L1CAM is considered to be a target of β-catenin, the key mediator of canonical Wnt signaling with a role in the contextual regulation of proliferation, decision points between ‘stemness’ and differentiation, cellular metabolism and EMT [39,43]. Since the microarray analysis revealed an upregulation of components that may contribute to canonical Wnt signaling in the chemoresistant cells (Fig 3A), the levels of β-catenin in the chemosensitive and chemoresistant cell lines were investigated. RNA levels of β-catenin were significantly
Fig 4. L1CAM is involved in proliferation and invasiveness of the 5-FU-resistant clones. (A) Control western blot showing the levels of L1CAM following transfection with esiRNA targeting L1CAM or control esiRNA, as described in Materials and methods. Actin is used as loading control. (B) Graph displaying number of invading cells (24 h invasion assays) following transfection with esiRNA targeting L1CAM or control esiRNA. Experiments were performed twice with similar results. Representative results are shown. (C) Graph displaying numbers of invading cells (48 h invasion assays) of cells treated with 2 μg/ml 5-FU.

Upregulation of L1CAM during Acquired 5-FU Resistance
increased (P < 0.05) in the chemoresistant clones (Fig 5A), but in the microarray the increase was less than two-fold and thus did not appear on the list of genes that were more than two-fold upregulated in the microarray (S1 Table). Western blots show no difference in the levels of total β-catenin protein between the chemosensitive and the chemoresistant cells, neither in the cytoplasm nor in the nucleus. (Fig 5A). Active β-catenin levels, as measured by an antibody detecting only active (unphosphorylated) protein, were not changed either (results not shown).

Slug did not show alterations in the microarray, which was also confirmed by RT-PCR (Fig 5B). However, a Western blot analysis showed a clear upregulation of Slug protein levels in both chemoresistant cell lines compared to the chemosensitive cell lines (Fig 5B). To test the impact of β-catenin and Slug on the expression of L1CAM, both β-catenin and Slug were targeted by esiRNA. Knockdown of Slug, but not β-catenin, lead to a decrease in L1CAM protein levels (Fig 5C and 5D). When Slug and β-catenin were knocked down simultaneously in the chemoresistant cells, no further reduction in the levels of L1CAM was observed (results not shown).

When assayed for invasiveness after Slug knockdown, B1Q and B1V cells displayed reduced invasiveness compared to the esiRNA control cells (24 h invasion; Fig 5E), in a similar manner to what was seen with knockdown of L1CAM (Fig 4B). Pretreatment with L1CAM antibody in addition to Slug knockdown did not further reduce the invasive ability of the chemoresistant lines (Fig 5E). Although the acquisition of 5-FU-resistance induced a multitude of changes in the Panc 03.27 pancreas adenocarcinoma cells, we identified L1CAM and its regulation through Slug as a major mediator of an invasive phenotype and acquired chemoresistance, and as a potential therapeutic target.

Discussion

5-FU was the systemic therapy of choice for advanced pancreatic cancer for many years, but in the late 90’s it was shown that the drug gemcitabine was superior to 5-FU in controlling disease-related symptoms [44]. However, 5-FU is still a recommended treatment option for pancreatic cancer today [45], and several recent studies have demonstrated a valuable role for 5-FU in combined treatment protocols compared with single gemcitabine chemotherapy [46,47].

Resistance to chemotherapeutic drugs is a major cause of treatment failure and poor prognosis in pancreatic cancer. In this study we have shown that the pancreatic cancer cell line Panc 03.27 subjected to long-term exposure to 5-FU developed resistance and acquired prototypical molecular features including upregulation of thymidylate synthase, survivin, and drug pumps. Further, we demonstrated that the chemoresistant cells became more mesenchymal-like and underwent EMT-related changes, including loss of epithelial markers (E-cadherin and CK19) and enhanced expression of the mesenchymal markers vimentin and N-cadherin, and the transcriptional factor Slug. We showed an upregulation of L1CAM in the 5-FU-resistant cells, which is in line with previous findings that support the hypothesis that L1CAM is upregulated by cancer cells as a part of the EMT process [13–18]. We were further able to link L1CAM to the process of EMT by demonstrating that the increased invasiveness of the chemoresistant cells was dependent on L1CAM, and that expression of L1CAM was dependent on
In line with this observation, Gavert et al. showed that stimulation of pancreatic ductal epithelial cells with TGF-β1 led to the acquisition of a spindle-shaped cell morphology and...
upregulation of mesenchymal proteins and L1CAM expression, which was dependent on JNK-mediated activation of Slug [40].

In the breast carcinoma cell line MCF7, upregulation of L1CAM has been shown to lead to disruption of E-cadherin-containing adherens junctions and thereby to increased transcriptional activity of β-catenin [48]. Activation of β-catenin contributed to sustained L1CAM expression and enhanced cell motility [48], which is in line with other evidence showing that LICAM is a target of β-catenin signaling [39]. However, our results did not show altered protein expression or localization of β-catenin in the chemoresistant cells, and more importantly, knockdown of β-catenin did not reduce levels of L1CAM, indicating that L1CAM expression was not regulated by β-catenin in these cells. Our results are thus in line with findings by Pfeifer et al. showing in endometrial carcinoma that Slug, and not β-catenin, is responsible for upregulation of L1CAM [41].

Overexpression of L1CAM has been shown to promote tumor cell proliferation, and inhibition of L1CAM expression or function can suppress proliferation [35–37]. Knockdown of L1CAM reduced proliferation in the chemoresistant Panc 03.27 cell lines (Fig 4D). This reduction in growth was not seen in the chemosensitive cell lines not expressing L1CAM. Our results point towards a specific role for L1CAM in the proliferation of 5-FU-resistant pancreatic cancer cells. Further work is needed to understand the effect of L1CAM on proliferation, however, other reports point towards a link to the Erk1/2 and the Akt-pathways, which both are known to accelerate proliferation and growth of tumor cells [35,37,49,50]. Furthermore, the reduced proliferation seen for the chemoresistant clones following L1CAM knockdown in Fig 4D can partly be a result of the slight increase in apoptosis seen in Fig 4F, following L1CAM knockdown.

Interestingly, the increased invasiveness displayed by our chemoresistant clones was reduced when L1CAM was knocked down, or when the extracellular part of L1CAM was blocked with an antibody. Increased invasiveness through upregulation of L1CAM is possibly one of many regulations downstream of Slug following induction of EMT.

There are some contradictory reports on the role L1CAM plays in the process of EMT. For instance, Gavert et al. recently showed that L1CAM mediated metastasis of colon cancer cells was dispensable for EMT induction and an altered expression of epithelial and mesenchymal marker proteins [51]. Further studies are required to elaborate whether upregulation of L1CAM is part of the EMT or even the inducing event. L1CAM might not be an EMT-mediator itself, but appears to be regulated by EMT-induced Slug, and once expressed it seems to drive invasion.

L1CAM has been shown to be involved in the mediation of chemoresistance against gemcitabine and etoposide in PDAC cell lines [38]. We investigated whether knockdown of L1CAM reduced the acquired resistance to 5-FU displayed by the cell line B1V. In our hands, L1CAM appeared to moderately protect cells from apoptosis in the absence of 5-FU, and more so in the presence of 5-FU.

Further studies are planned to investigate whether treatment with anti-L1CAM antibodies will reduce growth or metastasis of our 5-FU-resistant pancreatic cancer cell lines in vivo. The finding that pancreatic cancer cells with acquired resistance to 5-FU show increased expression of L1CAM, in addition to the distinction of L1CAM presence in cancerous vs. normal tissues [52], makes us hopeful that targeting of L1CAM with therapeutic antibodies and/or in combination with 5-FU could potentially benefit selected patients with refractory pancreatic tumors. Our findings provide further insight into the molecular mechanisms leading to a chemoresistant and migratory phenotype in pancreatic cancer cells and highlight the importance of addressing Slug-induced L1CAM expression in recurrent pancreatic cancer.
Materials and Methods

Cells and culture conditions

Panc 03.27 pancreatic adenocarcinoma cells were obtained from ATCC (CRL-2549) and cultured in RPMI medium (R8758, Sigma-Aldrich) containing 10% FBS (16000–044, Invitrogen) and penicillin/streptomycin (P/S, 17-603E, BioWhittaker), and 500 μl ITS (I3146, Sigma-Aldrich) at 37°C in a humidified atmosphere of 5% CO₂. Cell lines were detached using Accutase (L11–007, PAA).

5-FU-resistant cell line creation and clone isolation

Panc 03.27 5-FU-resistant cell lines were generated by continuous exposure of the tumor cells to 5-Fluorouracil (5-FU, F6627, Sigma-Aldrich) over a 6 month period. 5-FU was dissolved in DMSO (D8418, Sigma-Aldrich). Incubation began with 0.5 μg/ml 5-FU and increased to 1 μg/ml over time. After stable, proliferating lines resistant to 1 μg/ml 5-FU were created, clones were selected through limited dilution and clones derived from single cells were isolated and expanded over the next 3–4 months.

5-FU dose curve (proliferation assay)

Cells were plated at 1,500 cells per well in 96 well plates (Nunc) and allowed to attach overnight. The following morning media was replaced with 200 μl 5-FU containing media in a range from 0–10 μg/ml. The viability of the cells was determined by performing MTS assays according to manufacturer’s protocol (G3582, CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS), Promega), and absorbance at 490 nm was measured using an SLT SPECTRA plate reader (Perkin Elmer, Waltham, Massachusetts, USA). One plate was read before addition of 5-FU to serve as the initial absorbance reading. Plates were then read daily (once every 24 hours) for 6 days and growth was calculated by subtracting the background absorbance. Data represent means n = 6 for each data point.

Incucyte growth curves

24 hours after transfection with esiRNA, cells were detached using Accutase (L11–007, PAA) and replated at 1,500 cells per well in 96-well plates (Nunc). The plates were imaged using an IncuCyte FLR 20x (Essen BioScience, Ann Arbor, Michigan, USA), with phase contrast photos taken every 4 hours for the duration of the experiment, and % confluence was given as output. Graph in Fig 4D shows average percentage well coverage every 12 hours. Representative phase contrast images from the IncuCyte were used in Fig 2A (20x objective; scale bar attached to every image). Data represent means n = 6 for each data point.

Microarray hybridization and analysis

Microarray hybridizations (4 replicates per condition) were performed in the Norwegian Microarray and Sequencing Core Facility (Norwegian Microarray Consortium) at the Oslo University Hospital HF. First, 500 ng of total RNA was amplified and labeled using Illumina RNA TotalPrep Amplification kit according to manufacturer’s instructions. 750 ng of biotin labeled cRNA was hybridized to Illumina’s Human HT-12 v4 Expression BeadChip according to the manufacturer’s instructions. The probes on the Illumina chip are based on the content from the National Center for Biotechnology Information RefSeq database (HumanHT-12_V4_0_R2_15002873_B). The data were quantile normalized, and average of probe set signal per gene was used to calculated averages of signals across arrays in replicates.
Hybridizations and differential expression was assessed by calculating fold change in the B1V line versus the Nt line.

For ontology classifications, genes upregulated at least 2 fold in B1V versus the Nt cells were fed into HOMER (Hypergeometric Optimization of Motif EnRichment) [53] sub scripts findGO to retrieve enrichment calculated assuming cumulative hypergeometric distribution. The gene ontology of biological processes according to Wiki pathways was used to determine enriched pathways and only pathways with \( P < 0.05 \) were considered. (Microarray data can be found in GEOarchive, accession number GSE58386.)

**RT-PCR**

Total RNA was isolated using the GeneElute miniprep kit (Sigma) following the manufacturer’s instructions. cDNA was synthesized using the SuperScript VILO kit (11754050, Life Technologies), and real-time PCR was carried out using TaqMan gene expression master mix (4369016, Life Technologies) according to the manufacturer’s instructions on a StepOnePlus cycler (Life Technologies, Waltham, Massachusetts, USA). GAPDH was used to normalize the amount of cDNA in each sample and to guarantee the comparability of the calculated mRNA expression in all samples analyzed. In all real-time PCR graphs in Fig 2, the sample Nt is set to 1, and all samples are set relative to Nt. Error bars represent standard deviation. Statistically significant difference between Nt and B1V (\( P < 0.05 \)) is indicated by \( \ast \). To assess whether the real-time PCR results were significantly different we used the two-sided Students \( t \)-test by Sigma plot 2001. Data represent Means \( \pm \) SD; \( n \geq 3 \).

Probes were ordered from Life Technologies and were as follows:

- ABCB1-Hs00184500_m1
- ABCC5-Hs00981087_m1
- CTNNB1-Hs00355049_m1
- GAPDH-Hs02758991_g1
- Vimentin-Hs00185584_m1
- CDH1/Ecadherin-Hs01023894_m1
- CDH2/Ncadherin- Hs00983056_m1
- L1CAM- Hs01109748_m1
- SNAI2- Hs00950344_m1

**Invasion assay**

BD BioCoat matrigel invasion chamber 24-well plates; growth factor reduced; 8.0 \( \mu \)m pore size (354483, BD Biosciences) were used in the experiment as such; 25,000 cells (Fig 2J); 20,000 cells (Fig 4B and 4C); or 15 000 cells (Fig 5E) were plated in the top chamber in 500 \( \mu \)l of media containing 1% FBS and P/S. The bottom wells contained 750 \( \mu \)l of RPMI with 20% FBS. The cells were allowed to invade for 24 hours (Figs 2J, 4B, and 5E) or 48 (Fig 4C) hours, then the non-invading cells were scraped from the upper surface of the membrane with a cotton swab, and the cells on the lower side were stained with 0.02% crystal violet (HT90132, Sigma-Aldrich) in formaldehyde (F8775, Sigma-Aldrich). The number of invading cells was counted through the entire surface area (about 9 microscopic fields at 10x). In the antibody blocking experiment, cells were incubated in RPMI medium containing 1% FBS and P/S and either 2 \( \mu \)g/
ml mouse anti-L1CAM antibody (UJ127.11, Sigma), or 2 μg/ml mouse IgG isotype control antibody (sc-2025, Santa Cruz) for 1 hour at 4°C, before added to invasion assay. Antibody was also present during the invasion assay. Data represent Means ±SD; n = 3 for each data point. Each assay was run at least twice.

**Western blot**

Total cell extracts were made by adding cold TM buffer containing protease inhibitors (Total protein extraction kit, 2140, Millipore) to 80% confluent T25 flasks (136196, Nunc). Flasks were incubated on ice for 30 minutes and cells were collected using cell scrapers from Starstedt into 1.5 ml Eppendorf tubes, followed by centrifugation for 15 minutes at 13,000 rpm. Supernatant was transferred to another tube and protein concentration was measured using Bradford Assay (500–0205, Bio-Rad). Cytoplasmic and nuclear extracts: cells were detached using Accutase (L11–007, PAA), washed 1x in RPMI and 2x in PBS, and isolated using the Thermo NE-PER Nuclear and Cytoplasmic Extraction kit (78833, Thermo Scientific) per manufacturer's instructions. Protein concentration was measured using Bradford assay. Protein samples were loaded on to gels (Novex Bis-Tris or Tris-Acetate gels, Life Technologies) with PageRuler prestained protein ladder (26616, Fermentas) and run in Novex electrophoresis chambers (Life Technologies). Proteins were transferred to nitrocellulose membranes (LC2000, Novex, Life Technologies), blocked with 5% milk (A0830,0500, AppliChem), 0.05% tween-20 in TBS (09-7510-100, Medicago) for 1 hour, and stained with primary (4°C overnight with rocking in 5% milk, 0.05% tween-20 in TBS) and secondary antibodies (1 hour at room temperature with rocking in 5% milk, 0.1% tween-20 in TBS). Primary antibodies used; monoclonal mouse anti-active β-catenin (1:2000, 05–665, Millipore), monoclonal rabbit anti-Actin (1:2000, A5441, Sigma-Aldrich), monoclonal mouse anti-β-catenin (1:5000, 610154, BD Transduction Laboratories), polyclonal rabbit anti-CK19 (1 μg/ml, ab15463, Abcam), polyclonal rabbit anti-Lamin B1 (0.1 μg/ml, ab16048, Abcam), monoclonal rabbit anti-TS (1:1000, ab108995, Abcam), polyclonal goat anti-SLUG (1:100, sc-10436, Santa Cruz), monoclonal mouse anti-L1CAM (1:1000, L4543 (UJ127.11), Sigma-Aldrich), monoclonal rabbit anti-E-cadherin (1:500, ab15148, Abcam), monoclonal mouse anti-vimentin (1:1000, ab8978, Abcam), and polyclonal rabbit anti-survivin (1:1000, ab24479, Abcam). Secondary antibodies used are goat anti-mouse HRP or donkey anti-rabbit HRP (both 1:10000, sc-2005 and sc-2313, Santa Cruz). Bands were visualized using ECL plus (RPN2236, Amersham) on Amersham Hyperfilm (28906836, Amersham). Image Studio Lite (version 3.1.4) was used to quantify bands (normalized against loading controls).

**Flow cytometric analysis of L1CAM expression**

To investigate cell surface expression of L1CAM on the Panc 03.27 cell lines, flow cytometric analysis with PE-conjugated monoclonal anti-L1CAM antibody was performed (1:100, ab95694, Abcam). Cell lines were detached using Accutase (L11–007, PAA), washed 1x in RPMI and 2x in PBS, before they were resuspended in PBS containing anti-L1CAM-PE antibody, diluted 1:100. Cells were incubated at room temperature for 1 hour, before they were washed twice in PBS after antibody incubation. Acquisition of data was performed using an EasyCyte flow cytometer (GuavaTechnologies). A minimum of 5,000 cells were acquired per sample and exclusion of non-viable cells and debris was based on lower forward scatter and side scatter properties. Data analysis was performed using Flowing Software (Version 2.5.1).
Annexin V Assay (Flow cytometry)

To perform Annexin V assay on the Panc 03.27 cell lines, Annexin V FITC Assay (BD Biosciences) was used. Following esiRNA transfection and/or 5-FU treatment, cell lines were detached using Accutase, and spun at 300 rpm for 5 minutes together with used medium to collect released/dead cells. Medium was removed, and Annexin V was added to cells according to product protocol. Acquisition of data was performed using an EasyCyte flow cytometer (GuavaTechnologies). Exclusion of non-viable cells and debris was based on lower forward scatter and side scatter properties. Data analysis was performed using Flowing Software (Version 2.5.1).

Immunofluorescence

Cells were plated at 20,000 cells/well on coverslips in 24 well plates and allowed to attach overnight. Wells were fixed, permeabilized, and blocked as described previously [54]. Cells stained on cover slips were mounted on slides using Fluorescence Mounting Medium (S3023, DAKO). The coverslips were then incubated for 16 hours at 4°C with polyclonal rabbit anti-CK19 (10 μg/ml, ab15463, Abcam) or polyclonal rabbit anti-N-cadherin (1:100, ab76057, Abcam). Alexa Fluor 594 polyclonal goat anti-rabbit (1:700, A-11012, Life Technologies) was used as a secondary antibody in 1% BSA (A2153, Sigma-Aldrich) in PBS for 1 hour at room temperature. For L1CAM, monoclonal anti-L1CAM-PE (1:50, ab95694, Abcam) was used. Nuclei were counterstained with DAPI (1 μg/ml, 10236276001, Roche), in PBS for 5 minutes at room temperature. Images were obtained using an Axiovert 200M fluorescence microscope (Zeiss Axiovert 200 M, Carl Zeiss MicroImaging GmbH, Jena, Germany) with CCD camera (Zeiss Axiocam HR), using Axiovision software. All images are taken with 40x magnification.

esiRNA knockdown of β-catenin, L1CAM, and Slug

300,000 cells per well were plated in 6-well plates and allowed to attach overnight in an incubator at 37°C, and with 5% CO₂. The following morning, 30 nM of MISSION esiRNA targeting human CTNNB1 (β-catenin, EHU139421), human L1CAM (EHU100991), or human SNAI2 (Slug, EHU048191) or MISSION esiRNA EGFP (EHUEGFP) as ctrl (all from Sigma) per well was transfected using Lipofectamine 2000 (11668–019, Life Technologies), as per instructions. Cells were then returned to the incubator for 24 hours. After 24 hours, the cells were either detached and plated for further experiments (Immunostain, matrigel invasion assay) or left for 72 hours after change of medium (for RNA- and protein extractions).

Statistical analysis

To assess whether the data was significantly different we used the two-sided Student’s t-test by Sigma plot 2001. A minimum significance level of P < 0.05 was used.

Supporting Information

S1 Fig. Cluster analysis of gene expression in B1V and Nt. 607 genes with log2 change >1 were considered.
(PDF)

S1 Table. Upregulated genes. List of 319 genes upregulated at least 2-fold in the B1V clone compared to Nt clone of the Panc 03.27 cell line (P <0.05).
(PDF)
S2 Table. Downregulated genes. List of 288 genes downregulated at least 2-fold in the B1V clone compared to Nt clone of the Panc 03.27 cell line (P < 0.05).

Author Contributions
Conceived and designed the experiments: KL JLD NS SK. Performed the experiments: KL JLD NS. Analyzed the data: KL JLD NS AU IGM SK. Wrote the paper: KL. Contributed to the Materials and Methods part of the manuscript: JLD NS AU.

References
1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011 Aug 13378 (9791):607–20.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003 May 3(5):330–8. PMID: 12724731
3. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000 Nov 18(4):299–313. PMID: 11081567
4. Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 2012 Apr 40(4):1005–10. doi: 10.3892/ijo.2011.1300 PMID: 22179886
5. Harada K, Ferdous T, Ueyama Y. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol 2014 Apr 44(4):1302–8. doi: 10.3892/ijo.2014.2270 PMID: 24452636
6. Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012 Jan 13417(2):679–85.
7. Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys Res Commun 2009 Dec 18390(3):1061–5. doi: 10.1016/j.bbrc.2009.10.117 PMID: 19981116
8. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009 Jul 1569(14):5820–8. doi: 10.1158/0008-5472.CAN-08-2819 PMID: 19584296
9. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002 Jun 2(6):442–54. PMID: 12189386
10. Ginnebaugh KR, Ahmad A, Sarkar FH. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer. Expert Opin Ther Targets 2014 Apr 23.
11. Rathjen FG, Schachner M. Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J 1984 Jan 3(1):1–10. PMID: 6368220
12. Raveh S, Gavert N, Ben-Ze’ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009 Sep 18262(2):137–45.
13. Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E, et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 2012 Oct 14(10):715–20. doi: 10.1007/s12094-012-0866-3 PMID: 22911547
14. Geismann C, Artl A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011 Jan 38(1):257–66. PMID: 21109948
15. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010 Apr 220(5):551–61. doi: 10.1002/path.2675 PMID: 20077528
16. Kiefel H, Bondong S, Hazin J, Rilinger J, Schirmer U, Riedle S, et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 2012 Jul 6(4):374–84. doi: 10.4161/cam.20832 PMID: 22796939
17. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schaefer H, et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis 2012 Oct 33(10):1919–29. doi: 10.1093/carcin/bgs220 PMID: 22764136
18. Tischler V, Pfeifer M, Hausladen S, Schirmer U, Bonde AK, Kristiansen G, et al. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 2011 10:127. doi: 10.1186/1476-4598-10-127 PMID: 21985405

19. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010 Aug 17(8):2213–21. doi: 10.1245/s10434-010-0955-x PMID: 20162456

20. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, et al. Elevated L1CAM expression in precursor lesions and primary and metastatic tissues of pancreatic ductal adenocarcinoma. Oncol Rep 2010 Oct 24(4):909–15. PMID: 20811670

21. Tsutsumi S, Morohashi S, Kudo Y, Akasaka H, Ogasawara H, Ono M, et al. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J Surg Oncol 2011 Jun 1103(7):669–73. doi: 10.1002/jso.21880 PMID: 21360711

22. Johnstone PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995 Apr 155(7):1407–12.

23. Copur S, Alba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995 May 1749(10):1419–26.

24. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004 Feb 122(3):529–36.

25. De IS, De PA, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res 2008 Nov 28 (8B):3921–8. PMID: 19192650

26. Pratt S, Shepard RL, Kandasamy RA, Johnstone PA, Perry W III, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005 May 4(5):855–63. PMID: 15897250

27. Olle RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stathel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000 Jun 160(11):2805–9. PMID: 10850418

28. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001 Mar 2095 (2):92–5.

29. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007 Dec 14(12):3629–37. PMID: 17909916

30. Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, et al. Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. Experimental Cell Research 2010 Nov 15316(19):3172–81.

31. Kikuta K, Masamune A, Watanabe T, Ariga H, Itoh H, Hamada S, et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Physiol Res Commun 2010 Dec 17403(3–4):380–4. doi: 10.1016/j.bphr.2010.07.030

32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 Jan 7100(1):57–70.

33. Geissmann C, Arlt A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011 Jan 38(1):257–66. PMID: 21109948

34. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006 Jan 1566(2):936–43.

35. Min JK, Kim JM, Li S, Lee JW, Yoon H, Ryu CJ, et al. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin Cancer Res 2010 Jul 1516(14):3571–80. doi: 10.1158/1078-0432.CCR-09-3075 PMID: 20501614

36. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008 Feb 1568(4):1110–8.
38. Sebens MS, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007 Apr 2626(19):2759–68.

39. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005 Feb 14168(4):633–42.

40. Geismann C, Morscheck M, Koch D, Bergmann F, Ungrefen H, Arlt A, et al. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res 2009 May 1569(10):4517–26. doi: 10.1158/0008-5472.CAN-08-3493 PMID: 19435915

41. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 2010 11:64. doi: 10.1186/1471-2199-11-64 PMID: 20799950

42. Pan JJ, Yang MH. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol 2011 Sep 2(3):151–6. doi: 10.3978/j.issn.2078-6891.2011.022 PMID: 22181145

43. Blauwkamp TA, Nigam S, Ardehali R, Weissman IL, Nusse R. Endogenous Wnt signalling in human embryonic stem cells generates an equilibrium of distinct lineage-specified progenitors. Nat Commun 2012 3:1070. doi: 10.1038/ncomms2064 PMID: 22990866

44. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 Jun 15(6):2403–13. PMID: 9196156

45. Seufferlein T, Bachet JB, Van CE, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 Oct 23 Suppl 7:vii33–vii40. PMID: 22997452

46. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12364(19):1817–25.

47. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010 Sep 8304(10):1073–81. doi: 10.1001/jama.2010.1275 PMID: 20823433

48. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12364(19):1817–25.

49. Novak-Hofer I, Cohrs S, Grunberg J, Friedli A, Schlatter MC, Pfeifer M, et al. Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Lett 2008 Mar 18261(2):193–204.

50. Sebens S, Schafer H. The Adhesion Molecule L1CAM as a Novel Therapeutic Target for Treatment of Pancreatic Cancer Patients? In: Prof.Srivastava Sanjay, editor. Pancreatic Cancer- Molecular Mechanism and Targets. InTech; 2012. p. 329–44.

51. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010 May 2838(4):576–89.

52. Dembinski JL, Krauss S. A Distinct Slow-Cycling Cancer Stem-like Subpopulation of Pancreatic Adenocarcinoma Cells is maintained in Vivo. Cancers 2010 Nov 292(4):2011–25.